SLE-ILD: Comprehensive 15-Mark MD Exam Answer

1. INTRODUCTION & OVERVIEW

2. EPIDEMIOLOGY AND RISK FACTORS

3. SPECTRUM OF PULMONARY MANIFESTATIONS IN SLE

Table: Acute vs. Chronic Lung Syndromes in SLE (Fishman's, Table 58-2, p. 1022)

1. Community-acquired or immunocompromised pneumonia
2. Pleurisy
3. Pulmonary embolization
4. Uremic pneumonitis
5. Cardiogenic pulmonary edema
6. Acute reversible hypoxemia syndrome
7. Acute lupus pneumonitis
8. Diffuse alveolar hemorrhage (DAH)

1. Chronic diffuse interstitial lung disease (fibrosis)
2. Shrinking lung syndrome
3. Pulmonary arterial hypertension
4. Pleural disease (most common)

4. CHRONIC DIFFUSE ILD IN SLE

4a. Prevalence

• Clinical evidence of diffuse lung disease at onset: only 3% of SLE patients
• Interstitial fibrosis pattern developing during follow-up: < 5%
• Detectable interstitial changes on HRCT: up to 30% (subclinical)
• HRCT evidence of chronic ILD: reported in 3-11% with clinically significant disease

4b. Risk Factors for Pulmonary Fibrosis in SLE

• Increasing age and disease duration
• History of pleuritis
• Acute lupus pneumonitis (may progress to UIP)
• Specific autoantibodies (anti-Ro/SSA, anti-U1 RNP)
• Male sex
• Recurrent pulmonary infections

4c. Histopathologic Patterns (Murray & Nadel's Table 92.1)

1. NSIP (most common) - cellular or fibrotic subtypes
2. LIP (lymphocytic interstitial pneumonia)
3. OP (organizing pneumonia)
4. UIP - least common; often end-stage fibrosis

5. ACUTE LUPUS PNEUMONITIS

5a. Prevalence and Clinical Setting

• Occurs in < 5% of SLE patients (relatively uncommon but serious)
• 50% of cases may be the presenting manifestation of SLE
• More common postpartum
• Occurs during systemic flares (pleuritis, pericarditis, arthritis, nephritis)
• Frequently recurs and may progress to chronic UIP-pattern fibrosis

5b. Pathology

5c. Clinical Features

• Fever, dyspnea, cough (productive or non-productive)
• Hypoxemia, sometimes severe
• Mimics infectious pneumonia - impossible to distinguish clinically
• Associated with active systemic disease manifestations

5d. Investigations

• WBC elevated; ESR elevated
• Serum complement (C3, C4) often low
• ANA, anti-dsDNA - elevated in active disease
• BAL - hemorrhagic (if DAH coexists) or non-diagnostic; critical to exclude infection
• Chest X-ray: bilateral alveolar infiltrates (patchy or dense consolidation), often with pleural effusions and cardiomegaly (due to pericardial effusion or myocarditis)
• HRCT: ground-glass opacification, consolidation, often bilateral lower lobe predominant

5e. Prognosis

6. DIFFUSE ALVEOLAR HEMORRHAGE (DAH) IN SLE

6a. Epidemiology

• Occurs in 1.5-4% of SLE patients (Fishman's: 26% of severe SLE admissions in older series)
• Usually early in disease course
• More common with active lupus nephritis (most patients with DAH have concurrent active nephritis)
• Smokers at higher risk (increased alveolar permeability)

6b. Pathology

6c. Clinical Features

• Acute dyspnea over hours to days
• Fever
• Hemoptysis present in only 30% - absence does NOT rule out DAH
• Fall in hemoglobin - characteristic finding
• Elevated DLCO during active bleeding (DLCO paradoxically rises as hemoglobin absorbs CO)

6d. Investigations

• BAL: progressively hemorrhagic returns on serial lavage (diagnostic of DAH)
• HRCT: extensive ground-glass opacification and consolidation
• Elevated anti-dsDNA, low C3/C4
• Active urine sediment (RBC casts) indicating nephritis

6e. Management and Prognosis

1. High-dose IV corticosteroids (methylprednisolone 500-1000 mg/day x 3 days then taper)
2. Cyclophosphamide - for severe or refractory disease
3. Plasmapheresis - for resistant cases
4. IV immunoglobulin (IVIG)
5. Rituximab - emerging role in refractory cases

7. SHRINKING LUNG SYNDROME

• Occurs in < 1% of SLE patients
• Features: progressive exertional dyspnea, pleuritic chest pain, markedly reduced lung volumes with raised hemidiaphragms on CXR
• PFT: restrictive pattern with reduced TLC, VC; DLCO normal when corrected for KCO (transfer coefficient)
• Pathophysiology: debated - respiratory muscle weakness (diaphragmatic dysfunction) vs. pleural inflammation/adhesions vs. "unspecified chest wall restriction"
• Treatment: no proven therapy; some respond to corticosteroids or immunosuppressive therapy; usually self-limited

8. PULMONARY ARTERIAL HYPERTENSION (PAH) IN SLE

• Prevalence: 0.5-17.5% of SLE patients
• Preferentially affects younger women, SLE duration > 5 years
• Associated with: Raynaud phenomenon, serositis, anticardiolipin antibodies, anti-RNP antibodies
• 2-year survival < 50% in severe disease
• Mechanisms: vasoconstriction (primary), vasculitis, thromboembolism (antiphospholipid antibody syndrome)
• Diagnosis: echocardiography (screening) + right heart catheterization (definitive)
• Treatment: PAH-specific agents (prostanoids, endothelin receptor antagonists, PDE5-inhibitors) + corticosteroids/immunosuppression

9. PLEURAL DISEASE (Most Common Pulmonary Manifestation)

• Most common pulmonary manifestation of SLE
• Clinical/radiographic pleural involvement in 20% at onset; at least 50% at some time; autopsy prevalence 50-100%
• Effusions small and bilateral in 50%, often serosanguineous
• Pleural fluid: exudate, neutrophilic (acute) → lymphocytic (chronic)
• Pleural fluid ANA titer - diagnostically useful when etiology uncertain
• Often recurrent and occasionally intractable

10. PULMONARY EMBOLISM (Antiphospholipid Syndrome)

• PE occurs in up to 25% of SLE patients
• Correlates with antiphospholipid antibodies (lupus anticoagulant, anticardiolipin); anti-beta-2-glycoprotein I
• Up to 1/3 of SLE patients have antiphospholipid syndrome
• Associated: thrombocytopenia, recurrent arteriovenous thrombosis, hemolytic anemia, recurrent fetal loss, leg ulcers
• Must always be excluded before diagnosing "acute reversible hypoxemia syndrome"

11. ACUTE REVERSIBLE HYPOXEMIA SYNDROME

• Occurs during acute SLE exacerbations
• Hypoxemia + widened A-a gradient
• Normal CXR and V/Q scan (unlike pneumonitis or DAH)
• Mechanism: complement-activated neutrophil aggregation in pulmonary vasculature
• Treatment: immunosuppressive therapy (improves hypoxemia)
• Diagnosis of exclusion - PE must be ruled out first

12. HRCT PATTERNS IN SLE-ILD

13. AUTOANTIBODIES AND THEIR SIGNIFICANCE IN SLE-ILD

14. APPROACH TO TREATMENT OF SLE-ILD

General Principles

• SLE-ILD patients have underlying immune defects and are at risk for opportunistic infections with immunosuppressants - always distinguish ILD from infection first
• BAL is particularly important to exclude infection before escalating immunosuppression
• Drug-induced pulmonary reactions must be excluded (NSAIDs, antimalarials, methotrexate if used)

Acute Lupus Pneumonitis / Acute Exacerbation

1. High-dose corticosteroids - IV methylprednisolone 1g/day x 3 days, then oral prednisone 1 mg/kg/day
2. Cyclophosphamide - pulse IV cyclophosphamide for severe/refractory disease
3. Rituximab - emerging evidence in refractory cases
4. IVIG and plasmapheresis - used in resistant DAH

Chronic ILD (Fibrotic Disease)

1. Hydroxychloroquine - background therapy; immunomodulatory, reduces flares
2. Corticosteroids - first-line for active/progressive disease
3. Azathioprine or MMF - steroid-sparing agents for maintenance
4. Mycophenolate mofetil (MMF) - preferred maintenance agent; data primarily extrapolated from lupus nephritis and SSc-ILD trials

2026 ERS/EULAR CTD-ILD Guidelines Highlights (PMID: 40907995)

• Screening, diagnostic, monitoring, and treatment algorithms developed
• For SLE-ILD specifically: insufficient evidence was found to make definitive recommendations for ILD screening and risk-of-progression assessment (narrative question only - reflects the paucity of controlled SLE-ILD data)
• General CTD-ILD treatment recommendations emphasize:
  • MMF and azathioprine as preferred immunosuppressive agents
  • Rituximab for refractory disease
  • Nintedanib may be considered for progressive fibrotic CTD-ILD (evidence strongest for SSc-ILD; applicable to SLE-ILD as progressive phenotype)
  • Pirfenidone: insufficient evidence for CTD-ILD other than RA-ILD
  • Regular monitoring with PFTs (FVC, DLCO) and HRCT

15. SUMMARY COMPARISON TABLE: SLE vs Other CTD-ILD

KEY EXAM POINTS TO REMEMBER

1. SLE has the broadest spectrum of pulmonary involvement of any CTD - 8 distinct acute syndromes alone (Fishman's Table 58-2)
2. Pleuritis/pleural effusion = most COMMON pulmonary manifestation (50% at some point)
3. Chronic ILD is actually relatively UNCOMMON in SLE (<5-11%) compared to SSc
4. DAH = most life-threatening; mortality ~50%; hemoptysis present in only 30%; diagnosis by BAL
5. DLCO paradoxically elevated during active alveolar hemorrhage
6. NSIP = dominant histopathologic pattern of chronic ILD in SLE
7. Anti-RNP = associated with pulmonary vascular disease + shrinking lung syndrome
8. Antiphospholipid antibodies = associated with PE, PAH, thromboembolism - must always be excluded in acute dyspnea
9. BAL is critical to differentiate infectious pneumonia from lupus pneumonitis/DAH - misdiagnosis is dangerous
10. 2026 ERS/EULAR guidelines acknowledge insufficient evidence for SLE-ILD specific management - use expert consensus + extrapolation from SSc/RA-ILD data

• Fishman's Pulmonary Diseases and Disorders (Fishman's), Chapter 58 "SLE: Clinical Features" pp. 1022-1026
• Murray & Nadel's Textbook of Respiratory Medicine, Chapter 92 "Connective Tissue Disease" pp. 2082-2097
• Antoniou KM et al. ERS/EULAR clinical practice guidelines for CTD-ILD. Eur Respir J. 2026; [PMID: 40907995] and Ann Rheum Dis. 2026 [PMID: 40912974]
• Bendstrup E et al. "Systemic Lupus Erythematosus-related Lung Disease." Semin Respir Crit Care Med. 2024;45 [PMID: 38547915]